The DOI matches its Crossref record.
Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous melanoma trials observed substantially different outcomes between these populations in the phase III setting.
“It has been observed in previous trials of melanoma that outcomes appeared to be substantially different between these populations in the phase III setting (57).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Albrecht, L. J., Livingstone, E., Zimmer, L., & Schadendorf, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01406-4 · Cited by 49
Self-citationBigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma
Warner, A. B., & Postow, M. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1311 · Cited by 27
“For example, although limited due to being a descriptive, retrospective subgroup analysis, data from the Checkmate 067 study revealed that there was no obvious pattern to the relative benefit of nivolumabþ ipilimumab over nivolumab alone based upon a patient's tumor burden (2).”
Luke, J. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0876 · Cited by 21
“patients with BRAF-wild-type disease (possibly reflecting differences in the extent of advanced disease) [36].”
BackgroundChoice of first‐line therapy in metastatic melanoma
Gibney, G. T., & Atkins, M. B. (2019) · Cancer · doi:10.1002/cncr.31774 · Cited by 16
Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye
Sia, D. I. T., Thaung, C., O’Hanlon-Brown, C., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000443 · Cited by 10
Ascierto, P. A., Puzanov, I. J., Agarwala, S. S., Bifulco, C. B., Botti, G., Caracò, C., Ciliberto, G., Davies, M. A., Dummer, R., Ferrone, S., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1568-6 · Cited by 8
Self-citationFernandez-Diaz, A. B., García-Medina, A., Ferrer‐Guillén, B., et al. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000591 · Cited by 7
Metadata
- Authors
- Grob, J.-J., Schadendorf, D., Wagstaff, J., Márquez-Rodas, I., Lebbé, C., Ascierto, P. A., Hodi, F. S., Grossmann, K., Hassel, J. C., Walker, D., Bhore, R., Larkin, J., & Wolchok, J. D.
- Affiliations
- Hôpital de la Timone (FR)
- Essen University Hospital (DE)
- Singleton Hospital (GB)
- Inserm (FR)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Dana-Farber Cancer Institute (US)
- Huntsman Cancer Institute (US)
- Heidelberg University (DE)
- Bristol-Myers Squibb (United States) (US)
- Royal Marsden Hospital (GB)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 28
- Pages
- v432-v433
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2762632678
- Cited by
- 8
- References
- 0
- Citations by year
- 2023: 1 · 2019: 3 · 2018: 4
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Les Laboratories Pierre Fabre
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- advanced melanoma, nivolumab, ipilimumab, combination immunotherapy, overall survival, regional variation, CheckMate 067, post hoc analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
